☆ 4.8 Letter

Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity

CIRCULATION (2017)

Get Full Text
Add to Collection

Journal

CIRCULATION
Volume 136, Issue 21, Pages 2085-2087

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCULATIONAHA.117.030571

Keywords

cardiotoxicity; immunotherapy; neoplasms

Categories

Cardiac & Cardiovascular Systems Peripheral Vascular Disease

Funding

  1. MSD
  2. Janssen
  3. Merck
  4. Novartis
  5. AstraZeneca
  6. Bristol-Myers Squibb
  7. Amgen
  8. Sanofi
  9. Boston Scientific
  10. Bayer
  11. Boehringer Ingelheim
  12. Daiichi Sankyo
  13. GlaxoSmithKline
  14. Sanofi-Aventis
  15. Lilly
  16. Celgene
  17. Pfizer
  18. Esperare
  19. Philips Healthcare
  20. Ipsen
  21. Mark
  22. MDS

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.